FDA Approved: DOJOLVI — Original Application (Ultragenyx Pharmaceutical Inc.)

View source ↗

Summary

The FDA approved Dojolvi (triheptanoin) from Ultragenyx Pharmaceutical Inc. for the treatment of long-chain fatty acid oxidation disorders in pediatric and adul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long-chain Fatty Acid Oxidation Disorders

Drugs mentioned

• DOJOLVI (triheptanoin)

Snippet

ORIG AP for DOJOLVI (TRIHEPTANOIN)